GBT Guerbet SA
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab. In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women's health; and Patent Blue V, a pharmaceutical drug for breast cancer. The company was founded in 1901 and is headquartered in Villepinte, France.…
Industry Peers
Medical DevicesKey Statistics
About Guerbet (EPA: GBT)
›
Guerbet (EPA: GBT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 2,653 employees.
The shares were at 6.590 EUR on 19 November 2026, down 62.0% over 52 weeks. Its 52-week range is 5.800 EUR to 18.26 EUR: the price is 63.9% below the high and 13.6% above the low.
Its market capitalisation is 82.70M EUR.
Guerbet reports return on equity of -40.6%, an operating margin of -3.2% and revenue down 2.0% year over year.
Its debt exceeds its cash by 355.85M EUR, a debt-to-equity ratio of 1.65. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 7.650 EUR is 16.1% above the current price.